ArticleCurrent oncology (Toronto, Ont.)2016
Estimation of drug cost avoidance and pathology cost avoidance through participation in NCIC Clinical Trials Group phase III clinical trials in Canada.
Article in Current oncology (Toronto, Ont.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Financial impact of participating in oncology clinical trials in a tertiary hospital in Spain.BMC health services research · 2026Article
- Article
- The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.European journal of hospital pharmacy : science and practice · 2023Article
- Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain.BMC pulmonary medicine · 2023Article
- Drug cost avoidance analysis of cancer clinical trials in Spain: a study on cost contributors and their impact.BMC health services research · 2022Observational
- A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application.Frontiers in oncology · 2022Article
- The economic impact of compassionate use of medicines.BMC health services research · 2021Article
- Financial impact of the hospital pharmacy's participation in clinical trials.European journal of hospital pharmacy : science and practice · 2021Observational
- Barriers to conducting cancer trials in Canada: an analysis of key informant interviews.Current oncology (Toronto, Ont.) · 2020Article
- Computer physician order entry (CPOE) as a strategy to estimate laboratory activity and costs associated with cancer clinical trials.Biochemia medica · 2018Article
- The Economic Impact of Clinical Research in an Italian Public Hospital: The Malignant Pleural Mesothelioma Case Study.International journal of health policy and management · 2018Article
- Valorization of clinical trials from the Italian National Health Service perspective: definition and first application of a model to estimate avoided costs.Global & regional health technology assessmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCost avoidance occurs when, because of provision of a drug therapy [drug cost avoidance (dca)] or a pathology test [pathology cost avoidance (pca)] during trial participation, health care payers need not pay for standard treatments or testing. The aim of our study was to estimate the total dca and pca for Canadian patients enrolled in relevant phase iii trials conducted by the ncic Clinical Trials Group.
methodsPhase iii trials that had completed accrual and resulted in dca or pca were identified. The pca was calculated based on the number of patients screened and the test cost. The dca was estimated based on patients randomized, the protocol dosing regimen, drug cost, median dose intensity, and median duration of therapy. Costs are presented in Canadian dollars. No adjustment was made for inflation.
resultsFrom 1999 to 2011, 4 trials (1479 patients) resulted in pca and 17 trials (3195 patients) resulted in dca. The total pca was estimated at $4,194,849, which included testing for KRAS ($141,058), microsatellite instability ($18,600), and 21-gene recurrence score ($4,035,191). The total dca was estimated at $27,952,512, of which targeted therapy constituted 43% (five trials). The combined pca and dca was $32,147,361.
conclusionsOver the study period, trials conducted by the ncic Clinical Trials Group resulted in total cost avoidance (pca and dca) of approximately $7,518 per patient. Although not all trials lead to cost avoidance, such savings should be taken account when the financial impact of conducting clinical research is being considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.